Get started
Minerva Neurosciences, IncMinerva Neurosciences, IncMinerva Neurosciences, Inc

Minerva Neurosciences, Inc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NERV chart


Full chart

NERV upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪15.11 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.44 USD
Net income (FY)
‪−30.01 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪5.44 M‬
Beta (1Y)
0.54

Employees


Employees (FY)
9
Change (1Y)
0
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−3.33 M‬ USD

About Minerva Neurosciences, Inc


Sector
Health Technology
CEO
Rémy Henri Luthringer
Headquarters
Burlington
Website
minervaneurosciences.com
Founded
2007
FIGI
BBG0067S9Z73
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NERV news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NERV is 2.16 USD — it has increased by 0.93% in the past 24 hours. Watch Minerva Neurosciences, Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Minerva Neurosciences, Inc stocks are traded under the ticker NERV.
NERV stock has fallen by −1.82% compared to the previous week, the month change is a 0.47% rise, over the last year Minerva Neurosciences, Inc has showed a −67.76% decrease.
We've gathered analysts' opinions on Minerva Neurosciences, Inc future price: according to them, NERV price has a max estimate of 5.00 USD and a min estimate of 5.00 USD. Watch NERV chart and read a more detailed Minerva Neurosciences, Inc stock forecast: see what analysts think of Minerva Neurosciences, Inc and suggest that you do with its stocks.
NERV reached its all-time high on Jun 2, 2016 with the price of 126.72 USD, and its all-time low was 1.26 USD and was reached on Dec 29, 2022. View more price dynamics on NERV chart.
See other stocks reaching their highest and lowest prices.
NERV stock is 4.11% volatile and has beta coefficient of 0.54. Track Minerva Neurosciences, Inc stock price on the chart and check out the list of the most volatile stocks — is Minerva Neurosciences, Inc there?
Today Minerva Neurosciences, Inc has the market capitalization of ‪15.11 M‬, it has increased by 3.62% over the last week.
Yes, you can track Minerva Neurosciences, Inc financials in yearly and quarterly reports right on TradingView.
Minerva Neurosciences, Inc is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
NERV earnings for the last quarter are 2.97 USD per share, whereas the estimation was −1.01 USD resulting in a 394.06% surprise. The estimated earnings for the next quarter are −1.05 USD per share. See more details about Minerva Neurosciences, Inc earnings.
Minerva Neurosciences, Inc revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
NERV net income for the last quarter is ‪22.51 M‬ USD, while the quarter before that showed ‪−8.23 M‬ USD of net income which accounts for 373.43% change. Track more Minerva Neurosciences, Inc financial stats to get the full picture.
No, NERV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 9.00 employees. See our rating of the largest employees — is Minerva Neurosciences, Inc on this list?
Like other stocks, NERV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Minerva Neurosciences, Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Minerva Neurosciences, Inc technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Minerva Neurosciences, Inc stock shows the sell signal. See more of Minerva Neurosciences, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.